Cargando…
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
Neratinib (Nerlynx(®)) is an oral, irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor of HER1, HER2 and HER4. Neratinib therapy for 12 months significantly reduced the risk of invasive disease recurrence or death relative to placebo at both 2 and 5 years post-ran...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449300/ https://www.ncbi.nlm.nih.gov/pubmed/30607817 http://dx.doi.org/10.1007/s40261-018-0741-2 |